Anthropic wants to use Claude AI to help discover new lifesaving drugs, says 'the best way to identify and work through these bottlenecks is to get deeply involved in real drug programs'

Anthropic, an AI company, is expanding the use of its Claude AI system in various stages of drug development, as reported by Generate Biomedicines. The 70% reduction in CAR T-cell component length achieved through Claude's assistance led to immune cells producing roughly ten times more cancer-detecting receptors. Additionally, the modified cells exhibited enhanced cancer cell destruction capabilities and prolonged activity.

Claude has been deployed in collaborations with Generate Biomedicines, Divergence Labs, BigHat Biosciences, and Enveda to address challenges in cancer, food allergies, and rare muscular disorders. The AI system has generated potential antibody candidates, optimized antibody fragments, and analyzed manufacturing documentation, resulting in substantial time savings.

Anthropic's partnership with Bristol Myers Squibb aims to evaluate clinical study plans and estimate their success probability. Michael Pourdehnad, senior vice president for early clinical development at Bristol Myers Squibb, highlighted how Claude's initial analysis saved considerable time compared to traditional methods. The company plans to continue expanding Claude's involvement in drug development through further partnerships and research initiatives.